DPP-IV inhibitors: Beyond glycaemic control?

作者：Kwok Andrew J; Mashar Meghavi; Khavandi Kaivan; Sabir Ian^*

来源：Trends in Cardiovascular Medicine, 2014, 24(4): 157-164.

DOI：10.1016/j.tcm.2013.10.002

Dipeptidyl-peptidase-IV (DPP-IV) inhibitors are a new class of oral hypoglycaemic agents recently approved for the management of type 2 diabetes mellitus. Early data suggested that they had a positive impact on the cardiovascular system: treatment appeared to result in improvements in cardiac performance, blood pressure and lipid levels. However, recent clinical findings bring this into question. Our understanding of the physiological actions of these agents is complicated by the fact that DPP-IV has a wide range of substrates in addition to glucagon-like peptide 1. Indeed, DPP-IV inhibition alters concentrations of a wide variety of cytoldnes and neuropeptides. A deeper understanding of the physiological effects of these drugs as well as their true impact on cardiovascular risk is needed before consideration can be given to extending their use beyond the treatment of diabetes.

• 出版日期2014-5